anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Human Immunodeficiency Virus (HIV) causes AIDS, a life-threatening disease characterized by immunosuppressive, opportunistic infections and malignancies. Although many drugs have been approved over the past decade as suitable for use in the treatment of individuals with HIV, the need for antiviral drugs of greater efficiency is still pressing. One valuable source for antiviral bioactivity has been proven to be the natural products of a wide range of plants. In this study, we investigated the anti-reverse transcriptase (RT)-HIV-1 potential activity of  Avicennia marina  (gray mangrove) collected from the Red Sea shore, Saudi Arabia. Metabolites from  A. marina  were extracted using organic solvents followed by solid phase extraction (SPE) and high-performance liquid chromatography (HPLC). Gas chromatography mass spectrometry (GC-MS) was applied to assess the active HPLC fractions and to establish a correlation between the fractions&#39; chemical composition and biological activity. The chemical analyses revealed the existence of many polyphenol compounds. Polyphenol compounds have been proven to act as multi-target anti-HIV agents. Furthermore, imaging-based High-Content Screening (HCS) with a set of cellular staining was established to characterize mechanisms of activity and potential side-effects, such as toxicity and cell cycle arrest. In summary, we discovered and assessed for the first time anti-RT-HIV-1 activity for  A. marina  collected from Red Sea shore, Saudi Arabia. Our results suggest this plant is a promising candidate for the development of potential novel HIV-1 inhibitors.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a sheetlike pack material which contains CoQ10 and has effect of preventing skin disorder and regulating the skin in an excellent state.  &lt;P&gt;SOLUTION: The sheetlike pack material has constitution that one side of the material is equipped with a substrate 12 composed of a fiber layer and a paste 14 is laminated to the other side of the substrate 12. The paste 14 is water-containing gel of a water-soluble polymer material, CMC gel, agarose gel, oil gel, acrylic gel, etc. The paste 14 contains 0.1-10% of CoQ10 in a weight ratio. The paste 14 containing CoQ12 is pasted to the skin for many hours to supply CoQ12 to the skin for many hours.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a crosslinking polymer composition which carries out the adhesion between the surfaces of natural organizations and achieves the reinforcement of tissues, and to provide a usage thereof.  &lt;P&gt;SOLUTION: The crosslinking polymer composition comprises a first synthetic polymer having a plurality of nucleophilic groups which are to be bonded with covalent bonds to a second synthetic polymer having a plurality of electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol which is so modified as to contain a plurality of nucleophilic groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, and contains two or more electrophilic groups or is made for a derivative to contain them. This composition may contain still more other components. Additionally, by using the crosslinking polymer composition, a method for achieving the adhesion between a first surface and a second surface, one for carrying out the tissue reinforcement, one for preventing the surgical adhesion from forming and one for coating the surface of a synthetic implant, are also provided.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
This invention discloses a contraceptive hemostasis medicine and its preparation method. It grinds dried leech into fine powder and fills in capsule to obtain hemostasis pill; it washes, processes and decocts bighead atraclylodes rhizome, Chinese angelica pilose asiabell root, ligusticum root, peach kernel, baked ginger, chicken&#39;s gizzard skin, haematitum, achyranthes root and mother-wort, extracts them in 100 deg.C water twice, concentrates the liquid extract to a specific wt. of 1.3, collects the paste at 60 deg.C, makes extract, sugar powder and dextrin into a powder according to a proportion of 1:3:1, and dries it at a temp. of 70-80 deg.C to get granulated hemostasis powder. This invention features obvious quick effect, short curing course, no need of womb clearing and the aim reached only by oral taking. It has the advantages of abundant medicine resource, simple production, low-cost and no by-effect.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new nucleotide analog compound and its related compounds including a prodrug, and their therapeutic use and production.  &lt;P&gt;SOLUTION: This invention relates to a new nucleotide analog compound. This invention also relates to a use of the new compound or its medically acceptable ester or salt for a production of medical composition. This invention also relates to the medical composition for treatment of an infection, an invasion, a neoplasm or an autoimmune disease. This invention further relates to the new nucleotide analog compound modulating immune system including modulation of type 1 or 2 activity.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To readily recover superoxide dismutase in erythrocytes in high activity, by hemolyzing erythrocytes, subjecting the resultant hemolyzed solution to acidic or basic treatment, denaturing contaminating proteins, e.g. hemoglobin, etc., precipitating and separating the proteins and recovering the superoxide dismutase from the supernatant liquid. CONSTITUTION:Erythrocytes are hemolyzed and the pH of the resultant hemolyzed solution is once adjusted to &lt;=6.5 or &gt;=12 to denature hemoglobin. The pH of the above-mentioned hemolyzed solution is then adjusted to 7-8 to precipitate and separate contaminating proteins, e.g. hemoglobin, etc. Superoxide dismutase (hereinafter abbreviated to SOD) is recovered from the resultant supernatant. Since the contaminating proteins, e.g. hemoglobin, etc., present in large amounts in the hemolyzed solution can be removed simply by adding an acid or base, operation is readily carried out. The SOD in the above-mentioned supernatant liquid is purified by a conventional method, e.g. concentration, fractional precipitation, extraction with an organic solvent, ultrafiltration, affinity chromatography, etc.
The invention relates to a composition for strengthening an immune regulation function in a human body and applications thereof. The composition comprises effective components of panax japonicus saponin and panax japonicus polysaccharide or the effective components and an acceptable carrier on a health medicament, health food, health tea, health wine or a beverage. The composition has the function of improving the immune function of an immunocompromised mouse. In an animal model with a weak immune system caused by cyclophosphamide (Cy), the composition can enhance the spleen index of the immunocompromised mouse, enhance the proportions of CD&lt;4+&gt; to CD&lt;8+&gt; and B lymphocytes to NK cells, and increase the content of cell factors IL-2 and IFN-gamma. The composition enhances the medicament effect and the medical value of panax japonicus; therefore, the planting of medicinal materials and the development of medicaments can be promoted. The composition has better social and economic benefits.
&lt;P&gt;PROBLEM TO BE SOLVED: To use a nucleoside having a relatively low dosage range.  &lt;P&gt;SOLUTION: The administration of the nucleoside selectively modifying the reaction of Th1 and Th2, and other compound in the treatment of diseases decreases the dosage of an administered major medicine. In another aspect, an abnormality reflected on the increase of a reaction in one group of cytokines is treated by the administration of the nucleoside or other compound increasing the reaction of the other group of the cytokines. Further, in another aspect, by administering the nucleoside or other compound selectively decreasing the activity of the Th1 without significantly decreasing the activity of the Th2, patients can be treated preventively. Furthermore in another aspect, by a controlled release administration form, or the like, the nucleoside or other compound is administered to a patient by a dosage significantly decreasing a GTP (guanosine triphosphate) pool of the patient in an extent of selectively decreasing one of the reactions of the Th1 or Th2.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PROBLEM TO BE SOLVED: To obtain a cosmetic composition which can be used in treatment of skin, semi-mucous membrane and/or mucous membrane, particularly of lips and/or in make-up by using a combination of a specific fatty acid, a volatile compound and a specific amount of a non-volatile hydrocarbon oil. SOLUTION: A pasty or viscous fatty acid, a volatile compound and a non- volatile hydrocarbon oil in an amount of &lt;20wt.%, particularly &lt;5wt.% are contained in the fat phase to give the objective cosmetic composition. The fatty acid is lanolin, triglyceride and the like. The volatile compound is, for example, cyclotetradimethylsiloxane and is formulated in an amount of 8-70wt.% based on the whole of the composition. The use of this composition gives film which has markedly excellent shape retention and maintenance, occurs no phase transition, no staining of the contacting body and no migration with time. This composition can be used in foundation cosmetic, brusher, lipstick, mascara, eye liner and the like.
The subject&#39;s brain neurogenesis promoter of the present invention contains miR-30a, etc. or a vector which is for expressing miR-30a, etc. in the brain nerves of young and elderly subjects. The present invention also provides an agent for improving higher nervous function, an agent for improving memory learning function, a method for promoting brain neurogenesis, a method for improving higher nervous function, and a method for improving memory learning function. In the subject&#39;s brain neurogenesis promoter, etc. of the present invention, the subject may be an elderly subject.
Controlled-drug-delivery oral devices are implanted or inserted into an oral cavity, built onto a prosthetic tooth crown, a denture plate, braces, a dental implant, or the like. The devices are refilled or replaced as needed. The controlled drug delivery may be passive, based on a dosage form, or electro-mechanically controlled, for a high-precision, intelligent, drug delivery. Additionally, the controlled delivery may be any one of the following: delivery in accordance with a preprogrammed regimen, delivery at a controlled rate, delayed delivery, pulsatile delivery, chronotherapeutic delivery, closed-loop delivery, responsive to a sensor&#39;s input, delivery on demand from a personal extracorporeal system, delivery regimen specified by a personal extracorporeal system, delivery on demand from a monitoring center, via a personal extracorporeal system, and delivery regimen specified by a monitoring center, via a personal extracorporeal system. Drug absorption in the oral cavity may be assisted or induced by a transport mechanism, such as any one of, or a combination of iontophoresis, electroosmosis, electrophoresis, electroporation, sonophoresis, and ablation. The oral devices require refilling or replacement at relatively long intervals of weeks or months, maintain a desired dosage level in the oral cavity, hence in the gastrointestinal tract, for extended periods, address situations of narrow drug therapeutic indices, and by being automatic, ensure adherence to a prescribed medication regimen. The oral devices and methods for controlled drug delivery apply to humans and animals.
1308264 I-N-Benzyl-#-methoxy-3-trifluoromethyl-phenylethylamine SMITH KLINE &amp; FRENCH LABORATORIES 27 July 1971 [28 July 1970] 35156/71 Heading C2C [Also in Division A5] The title compound is prepared by treating the dl form in a lower alkanol with an optically active levorotatory organic acid to form the corresponding optically active salt which is then treated with a base to liberate the l-isomer. Alternatively an aqueous lower alkanol solution of the racemic mixture is treated with an optically active organic acid, (e.g. D-tartaric acid) to remove the d-isomer of the amine then the mother liquor is made basic and subsequently treated with the corresponding enantiomer of the optically active organic acid (e.g. L-tartaric acid) to form a salt from which the l-isomer of the amine is subsequently liberated. The title compound may be. converted into pharmaceutically acceptable acid addition salts such as the hydrochloride.
PURPOSE: A composition containing Xanthium strumarium var. japonicum HARA is provided to reduce toxicity and side effects and to treat skin disorders such as skin inflammation and athlete&#39;s foot. CONSTITUTION: A method for manufacturing a composition for promoting skin regeneration containing a crude drug ingredient comprises: a step of washing Xanthium strumarium var. japonicum HARA and completely drying; a step of adding 1.5 times volume of Xanthium strumarium var. japonicum HARA and heating with weak fire for 12-24 hours to obtain a Xanthium strumarium var. japonicum HARA extract; a step of mixing 50-70 parts by weight of a concentrate liquid of hot water extract of Xanthium strumarium var. japonicum HARA, 5-10 parts by weight of vaseline, 3-10 parts by weight of Canavalia gladiate powder, 10-15 parts by weight of liquid paraffin, 1-5 parts by weight of beeswax, 4-10 parts by weight of cetanol, 3-5 parts by weight of polysorbate 1-3 parts by weight of mono stearic acid sorbitan, 5-10 parts by weight of propylene glycol, 0.1-0.5 parts by weight of methyl para-hydroxybenzoate, and 0.1-0.5 parts by weight of propyl para-hydroxybenzoate; a step of boiling the mixture in a water bath at 80-90 deg. C; and a step of cooling the mixture.
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to dentistry, namely to methods of treating glossalgia. Physiotherapeutic treatment is combined with drug therapy with antidepressants, anxiolytics, vitamins, dental gel, such as Phenazepam 0.5 mg at night, Amitriptyline 25 mg 2 times a day, Milgamma 2 ml intramuscularly, Cholisal in form of applications. As a physiotherapeutic treatment laser radiation of red spectrum of action and negative pressure of the manipulative holder of complex KAP-&#34;Parodontolog&#34; on painful zones of tongue are used. It is exposed to continuous laser radiation of wave length 0.65 mcm with further transition to laser beam modulation at first frequency of 1 Hz in the middle of the course, and then 10 Hz to its end and negative pressure with minimum pressure of 0.45 kgf/cm. Middle rate discharge is gradually increased to 0.55 kg/cmand then to 0.65 kgf/cmto its end. Total exposure time is increased by ascending order from 5 to 15 minutes. Complete therapeutic course makes 8–10 daily sessions.EFFECT: method enables prolonging the remission, analgesia, considerably reducing the paresthesia sensations, improving microcirculation and correction of the patient&#39;s psychoemotional status.1 cl, 2 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide isolated receptors, to provide DNAs encoding such receptors, and to provide pharmaceutical compositions made therefrom.  &lt;P&gt;SOLUTION: Isolated DNAs encoding RANK polypeptides at least 80% identical to natural type RANKs with respect to amino acid sequences. The RANK polypeptides can be prepared by obtaining recombinant expression vectors containing the DNA sequences and then culturing host cells transformed with the vectors. The isolated receptors can be used to regulate immune responses. The receptors are also useful in screening for inhibitors thereof.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an improved medical solution which can easily be produced, stably and aseptically be maintained under a preservation condition, and easily and effectively be used during medical therapy such as dialysis therapy.  &lt;P&gt;SOLUTION: A glucose polymer-based solution and a method for making the glucose polymer-based solution that can be used during medical therapy such as dialysis therapy are provided. This glucose polymer-based solution preferably includes a first solution containing icodextrin at a pH ranging from about 1.5 to about 5.0 and a buffer solution at a pH ranging from about 7.0 to about 12.0. These first solution and buffer solution are constructed and arranged so as to allow the glucose polymer-based solution to be mixed prior to infusion into a patient. The glucose polymer-based solution can be made at a physiologic pH and with a minimal glucose degradation product.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention relates to the establishment, implementation and management of a personalised information system pertinent to any user&#39;s general health, wellness, and/or sport performance. The novel set of portable devices includes calorimeter, metabolism sensor, and calculation and communication capacities employed for continuous, real time measurement and displaying, as well for long-term, precise information data collection of user&#39;s metabolic condition. Real-time response to user&#39;s respiratory factor (RQ) and presentation of other data. The novel system has two batteries and can support uninterruptible power supply, and it may be employed for electronic components. The personalised information system additionally designed for presentation of measured and calculated metabolic parameters as regards manual control of user&#39;s specific purposes during short or long times. The system may be operated continuously in order to determine real-time dietetic condition, amount of energy obtained, and energy consumption level, and it can provide subsequent personal dietetic instructions and exercise instructions for increasing user&#39;s efficiency in achievement and maintenance of his/her defined general health, wellness, and/or sport performance. The invention also integrates user&#39;s information such as, without limitation, energy consumption and real-time energetic balance, into social/game networks and other social interactions.
PURPOSE: To obtain a compsn. for cosmetics or for dermatological pharmacy made of an aq. dispersion of lipid vesicles. CONSTITUTION: The constituent lipids of at least some partition wall layers of the vesicles include 50-75% phospholipid and 50-25% glycolipid contg. 1-5% ganglioside. These lipids may be extracted from the membranes of small fat spheres of mammalian milk, especially cow&#39;s butter milk.
Methods and systems for diagnosing a bone disease related to collagen pathology in a subject are provided. These include providing a bone sample from the subject and determining a quantitative collagen morphology value of the bone sample. A reference value is provided from a non-affected control subject where the reference value is a quantitative collagen morphology value from the same type of bone sample obtained from a population of non-affected control subjects. The quantitative collagen morphology value of the subject&#39;s bone sample is compared to the reference value. If the collagen morphology value is altered versus the reference value, the subject is diagnosed as having a collagen related bone disease. The collagen morphology value can include mean fibril spacings and distributions of the fibril spacings taken from a subject&#39;s bone sample.
Method for digitally determining the daily insulin regimen for a diabetic patient. The invention divides the patient&#39;s day into adjustable time intervals containing basal insulin dosage rates and Carbohydrate-to-Insulin Ratio(s) (for determining meal insulin doses). The invention identifies the Corrective Insulin doses over a time interval as an &#34;error&#34; in the Prescription Insulin (Basal Insulin + Meal Insulin). Methods involve first estimating the change to one of these two components of Prescription Insulin, and then determining the change to the other by subtracting from the error. One method estimates Change in Meal Insulin distributed among intervals proportional to old Meal Insulin. Another method lumps After-Meal Corrective Insulin together with Meal Insulin. Another method splits the interval at the After-Meal Corrective Dose and determines Basal from Time-Boundary Corrective Dose. Data may be obtained from the previous day, and a small fraction of error applied, leading to asymptotic reduction of error. Data may be obtained from recent history, and a larger fraction of error applied by doctor or automatic method.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a medicine using Acanthopanax senticosus Harms having high effect on Parkinson&#39;s disease and to provide a method for producing the medicine from Acanthopanax senticosus Harms.  &lt;P&gt;SOLUTION: The surface (at least about 5% of cross-section area) of terrestrial stem of Acanthopanax senticosus Harms is roasted and essence is extracted by using warm water at about 60°C for about two nights and two days. The essence is subjected to centrifugation and separated into an extracted solution 1 and a residue 1. The residue 1 is incorporated with three times as much as hot water (about 100°C), extracted for about one night and one day, subjected to centrifugation and separated into an extracted solution 2 and a residue. The extracted solution 1 is mixed with the extracted solution 2, concentrated until the liquid amount is reduced to half to give MASH0312 having prevention effect on Parkinson&#39;s disease.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain a new compound to be used as an active ingredient for medicinal compositions, esp. having production-controlling effect on tumor necrotic factors and vascularization inhibitory activity and/or aminopeptidase N inhibitory activity. SOLUTION: This new compound (salt) is shown by formula I (R is adamanthyl or 2,6-diisopropylphenyl; X is nitro, amino, cyano, trifluoromethyl, hydroxy, a halogen or lower alkyl; Y and Z are each O or S; (m) is 0-4; (n) is 0 or 1), e.g. N-(2,6-diisopropylphenyl)isoindoline. The compound of formula I is obtained by reaction between a compound of formula II and a compound of the formula R-NH2 (when Y is O and (n) is zero). The other objective medicinal composition containing this new composition is useful for treating such immunological diseases as graft rejection, rheumatic fever, Behcet&#39;s disease and aphthous ulcer, and for prophylaxis/treatment of inflammatory diseases and allergic diseases.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a quickly disintegrable tablet which comprises a powder compression molded product having a high strength but having a low density and is excellent in a disintegration property in liquids.  &lt;P&gt;SOLUTION: This disintegrable tablet is obtained by compressing a powder mixture comprising the powder of a raw material and a polymer binder which is solid at ordinary temperature and has a melting point of ≤100°C, and has a porosity of 20 to 40 vol.%. This disintegrable tablet is preferably obtained by compressing the mixture, while giving ultrasonic wave oscillations. The powder of the raw material as the main agent preferably has a weight-average particle diameter of 20 to 300 μm and a coefficient of variation of ≤50%. The method for producing the disintegrable tablet comprises filling a mold for table molding with the powder mixture, and then giving a compression force to at least one of molding pestles oppositely disposed on both the sides of the powder mixture, while giving ultrasonic wave oscillations to the powder mixture.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT